Metabolomic analysis of 92 pulmonary embolism patients from a nested case-control study identifies metabolites associated with adverse clinical outcomes

J Thromb Haemost. 2018 Mar;16(3):500-507. doi: 10.1111/jth.13937. Epub 2018 Jan 30.

Abstract

Essentials Risk-stratification often fails to predict clinical deterioration in pulmonary embolism (PE). First-ever high-throughput metabolomics analysis of risk-stratified PE patients. Changes in circulating metabolites reflect a compromised energy metabolism in PE. Metabolites play a key role in the pathophysiology and risk stratification of PE.

Summary: Background Patients with acute pulmonary embolism (PE) exhibit wide variation in clinical presentation and outcomes. Our understanding of the pathophysiologic mechanisms differentiating low-risk and high-risk PE is limited, so current risk-stratification efforts often fail to predict clinical deterioration and are insufficient to guide management. Objectives To improve our understanding of the physiology differentiating low-risk from high-risk PE, we conducted the first-ever high-throughput metabolomics analysis (843 named metabolites) comparing PE patients across risk strata within a nested case-control study. Patients/methods We enrolled 92 patients diagnosed with acute PE and collected plasma within 24 h of PE diagnosis. We used linear regression and pathway analysis to identify metabolites and pathways associated with PE risk-strata. Results When we compared 46 low-risk with 46 intermediate/high-risk PEs, 50 metabolites were significantly different after multiple testing correction. These metabolites were enriched in the following pathways: tricarboxylic acid (TCA) cycle, fatty acid metabolism (acyl carnitine) and purine metabolism, (hypo)xanthine/inosine containing. Additionally, energy, nucleotide and amino acid pathways were downregulated in intermediate/high-risk PE patients. When we compared 28 intermediate-risk with 18 high-risk PE patients, 41 metabolites differed at a nominal P-value level. These metabolites were enriched in fatty acid metabolism (acyl cholines), and hemoglobin and porphyrin metabolism. Conclusion Our results suggest that high-throughput metabolomics can provide insight into the pathophysiology of PE. Specifically, changes in circulating metabolites reflect compromised energy metabolism in intermediate/high-risk PE patients. These findings demonstrate the important role metabolites play in the pathophysiology of PE and highlight metabolomics as a potential tool for risk stratification of PE.

Keywords: metabolism; metabolomics; pulmonary embolism; risk; venous thromboembolism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Carnitine / analogs & derivatives
  • Carnitine / metabolism
  • Case-Control Studies
  • Fatty Acids / metabolism
  • Female
  • Hemoglobins / metabolism
  • Humans
  • Hypoxanthine / metabolism
  • Inosine / metabolism
  • Male
  • Metabolome*
  • Middle Aged
  • Porphyrins / metabolism
  • Prospective Studies
  • Pulmonary Embolism / blood*
  • Pulmonary Embolism / therapy*
  • Purines / metabolism
  • Risk Assessment
  • Treatment Outcome*
  • Tricarboxylic Acids / metabolism
  • Young Adult

Substances

  • Fatty Acids
  • Hemoglobins
  • Porphyrins
  • Purines
  • Tricarboxylic Acids
  • acylcarnitine
  • Hypoxanthine
  • Inosine
  • Carnitine